Tocilizumab for severe COVID-19 pneumonia – Authors' reply
Giovanni Guaraldi, Marianna Meschiari, Jovana Milić, Alessandro Cozzi‐Lepri, Cristina Mussini
Topics & Concepts
TocilizumabCoronavirus disease 2019 (COVID-19)Pneumonia2019-20 coronavirus outbreakMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyIntensive care medicineInternal medicineInfectious disease (medical specialty)OutbreakRheumatoid arthritisDiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research